PubRank

Thierry Lambert

Author PubWeight™ 57.02‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Diversity of CTX-M beta-lactamases and their promoter regions from Enterobacteriaceae isolated in three Parisian hospitals. FEMS Microbiol Lett 2002 4.36
2 Contribution of acquired carbapenem-hydrolyzing oxacillinases to carbapenem resistance in Acinetobacter baumannii. Antimicrob Agents Chemother 2005 3.41
3 Plasmid-mediated high-level resistance to aminoglycosides in Enterobacteriaceae due to 16S rRNA methylation. Antimicrob Agents Chemother 2003 3.22
4 Expression of the RND-type efflux pump AdeABC in Acinetobacter baumannii is regulated by the AdeRS two-component system. Antimicrob Agents Chemother 2004 2.89
5 ColE1-like plasmid pIP843 of Klebsiella pneumoniae encoding extended-spectrum beta-lactamase CTX-M-17. Antimicrob Agents Chemother 2002 2.21
6 AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii. Antimicrob Agents Chemother 2007 2.04
7 Distribution of extended-spectrum beta-lactamases in clinical isolates of Enterobacteriaceae in Vietnam. Antimicrob Agents Chemother 2002 1.94
8 Overexpression of resistance-nodulation-cell division pump AdeFGH confers multidrug resistance in Acinetobacter baumannii. Antimicrob Agents Chemother 2010 1.58
9 Hemophilia A induced by ipilimumab. N Engl J Med 2011 1.55
10 Acquired hemophilia in older people: a poor prognosis despite intensive care. J Am Geriatr Soc 2007 1.54
11 RmtF, a new member of the aminoglycoside resistance 16S rRNA N7 G1405 methyltransferase family. Antimicrob Agents Chemother 2012 1.49
12 Sequence of conjugative plasmid pIP1206 mediating resistance to aminoglycosides by 16S rRNA methylation and to hydrophilic fluoroquinolones by efflux. Antimicrob Agents Chemother 2008 1.44
13 Transfer of vancomycin resistance transposon Tn1549 from Clostridium symbiosum to Enterococcus spp. in the gut of gnotobiotic mice. Antimicrob Agents Chemother 2006 1.43
14 GES-11, a novel integron-associated GES variant in Acinetobacter baumannii. Antimicrob Agents Chemother 2009 1.36
15 Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2005 1.33
16 Complex genetic structures with repeated elements, a sul-type class 1 integron, and the blaVEB extended-spectrum beta-lactamase gene. Antimicrob Agents Chemother 2006 1.23
17 Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project. Thromb Haemost 2015 1.20
18 Integron-associated antibiotic resistance in Salmonella enterica serovar typhi from Asia. Antimicrob Agents Chemother 2003 1.16
19 Native valve endocarditis due to Enterococcus hirae. J Clin Microbiol 2002 1.15
20 Immune tolerance induction in patients with severe hemophilia with inhibitors: expert panel views and recommendations for clinical practice. Eur J Haematol 2012 0.98
21 Aminoglycoside resistance gene ant(4')-IIb of Pseudomonas aeruginosa BM4492, a clinical isolate from Bulgaria. Antimicrob Agents Chemother 2003 0.92
22 The cme gene of Clostridium difficile confers multidrug resistance in Enterococcus faecalis. FEMS Microbiol Lett 2004 0.91
23 The functional vanGCd cluster of Clostridium difficile does not confer vancomycin resistance. Mol Microbiol 2013 0.88
24 Analysis of the mobilization functions of the vancomycin resistance transposon Tn1549, a member of a new family of conjugative elements. J Bacteriol 2009 0.88
25 Clostridium clostridioforme and Atopobium minutum clinical isolates with vanB-type resistance in France. J Clin Microbiol 2011 0.88
26 Protein A Sepharose immunoadsorption can restore the efficacy of platelet concentrates in patients with Glanzmann's thrombasthenia and anti-glycoprotein IIb-IIIa antibodies. Br J Haematol 2002 0.87
27 Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood 2002 0.87
28 Distribution of the vanG-like gene cluster in Clostridium difficile clinical isolates. Can J Microbiol 2012 0.85
29 Circulating microparticles are elevated in haemophiliacs and non-haemophilic individuals aged <18 years. Br J Haematol 2005 0.85
30 Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting. Thromb Haemost 2008 0.84
31 Reappraisal of in utero stem cell transplantation based on long-term results. Fetal Diagn Ther 2004 0.84
32 Beyond patient benefit: clinical development in hemophilia. Hematology 2012 0.82
33 Epidemiological survey of haemophiliacs with inhibitors in France: orthopaedic status, quality of life and cost--the 'Statut Orthopédique des Patients Hémophiles' avec Inhibiteur study. Blood Coagul Fibrinolysis 2009 0.81
34 Intestinal surgery with activated recombinant factor VII prophylaxis in patients with haemophilia A and high responding inhibitors: a report of five cases. Blood Coagul Fibrinolysis 2004 0.81
35 Genetic and biochemical characterization of OXA-63, a new class D beta-lactamase from Brachyspira pilosicoli BM4442. Antimicrob Agents Chemother 2008 0.81
36 Detection of 95 novel mutations in coagulation factor VIII gene F8 responsible for hemophilia A: results from a single institution. Hum Mutat 2006 0.80
37 PRO-PACT: retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitors. Thromb Res 2012 0.78
38 Pseudo-outbreak of Oxa-23-mediated carbapenem-resistant Acinetobacter baumannii in urinary tract infections caused by an automated urine analyzer. Infect Control Hosp Epidemiol 2014 0.77
39 Emergence and dissemination of a new mechanism of resistance to aminoglycosides in Gram-negative bacteria: 16S rRNA methylation. Euro Surveill 2005 0.76
40 Determinants of drug costs in hopitalised patients with haemophilia: impact of recombinant activated factor VII. Pharmacoeconomics 2003 0.76
41 Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Results of a phase 3 trial. Thromb Haemost 2016 0.76
42 Injection of recombinant activated factor VII can induce transient increase in circulating procoagulant microparticles. Thromb Haemost 2004 0.75
43 Inhibitor development in non-severe haemophilia across Europe. Thromb Haemost 2015 0.75
44 Pain and pain management in haemophilia. Blood Coagul Fibrinolysis 2016 0.75
45 Switching treatments in haemophilia: is there a risk of inhibitor development? Eur J Haematol 2014 0.75
46 Rationale for individualizing haemophilia care. Blood Coagul Fibrinolysis 2015 0.75
47 Acquired haemophilia A associated with HIV infection: a rare disease. AIDS 2014 0.75